Adrenal Clinical

ea0029oc7.1 | Adrenal Clinical | ICEECE2012

Progression-free survival without treatment of malignant pheochromocytoma and paraganglioma at one year

Hescot S. , Leboulleux S. , Amar L. , Borget I. , Vezzosi D. , Libe R. , Niccoli P. , Borson-Chazot F. , Do Cao C. , Tabarin A. , de la Fouchardiere C. , Raingeard I. , Chougnet C. , Gimenez-Roqueplo A. , Young J. , Bertherat J. , Wemeau J. , Bertagna X. , Schlumberger M. , Plouin P. , Baudin E.

Pheochromocytoma and paraganglioma are defined as malignant by the occurence of metastasis in extra paraganglionic sites. The natural evolution of these tumors remains unknown.The aim of our retrospective study was to define the progression-free survival (PFS) of untreated Malignant Pheochromocytoma and Paraganglioma (MPP) at 12 months (12 m-PFS) and to look for prognostic markers of 12 m-PFS. We analyzed clinical parameters of patients followed within 8...

0 shares

ea0029oc7.2 | Adrenal Clinical | ICEECE2012

Activation of the PKA pathway triggers formation of an illicit serotonergic regulatory loop in primary pigmented nodular adrenal disease (PPNAD) tissues associated with Cushing’s syndrome

Bram Z. , Renouf S. , Duparc C. , Ragazzon B. , Libe R. , Martinez A. , Stratakis C. , Bertherat J. , Louiset E. , Lefebvre H.

In the normal adrenal gland, serotonin (5-HT) stimulates cortisol secretion through activation of 5-HT4 receptors whereas, in some macronodular adrenal hyperplasia tissues, the corticotropic effect of 5-HT is mediated by ectopic 5-HT7 receptors. The aim of the present study was to investigate the role of 5-HT in the control of cortisol secretion in PPNAD tissues from 12 patients by using molecular, immunohistochemical and pharmacological approaches. RT-PCR studies revealed ove...

0 shares

ea0029oc7.3 | Adrenal Clinical | ICEECE2012

Ribonucleotide reductase large subunit (RRM1) gene expression predicts efficacy of adjuvant mitotane in adrenocortical cancer

Volante M. , Terzolo M. , Fassnacht M. , Rapa I. , Germano A. , Sbiera S. , Daffara F. , Sperone P. , Scagliotti G. , Allolio B. , Papotti M. , Berruti A.

Purpose: Mitotane is the reference systemic therapy for adrenocortical carcinoma (ACC), but its mechanism of action and possible predictors of treatment response remain poorly defined. Our aim was to evaluate the gene expression of ribonucleotide reductase large subunit 1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) in ACC as potential biomarkers for clinical outcome and response to mitotane.Experimental design: Forty-five and 47 tiss...

0 shares

ea0029oc7.4 | Adrenal Clinical | ICEECE2012

Differential diagnosis of primary aldosteronism by peripheral plasma levels of 18-oxo-cortisol: a noninvasive method with a high specificity

Satoh F. , Morimoto R. , Kudo M. , Iwakura Y. , Ono Y. , Takase K. , Nakamura Y. , Sasano H. , Ito S.

18-Oxocortisol (18-oxoF) is a derivative of cortisol (F) that is produced by aldosterone synthase (CYP11B2), and its clinical usefulness has not been clarified. We prospectively measured 18-oxoF, using highly sensitive liquid chromatography-tandem mass spectrometry (LC/MS/MS), in peripheral plasma of patients with primary aldosteronism (PA) who underwent adrenal venous sampling (AVS) to differentiate aldosterone producing adenoma (APA) from bilateral hyperplasia. The study was...

0 shares

ea0029oc7.5 | Adrenal Clinical | ICEECE2012

Continuous subcutaneous hydrocortisone infusion (CSHI) as replacement therapy in Addison’s disease (AD)

Oksnes M. , Bjornsdottir S. , Methlie P. , Bratland E. , Isaksson M. , Kampe O. , Hulting A. , Bensing S. , Husebye E. , Lovas K.

Background: Conventional glucocorticoid replacement therapy is unphysiological, and does not restore quality-of-life in AD. Here we evaluated the dosing regimens and glucocorticoid metabolism in 10 patients undergoing 24 h sampling during oral replacement therapy and CSHI.Design, Subjects, Measurements: We set up a cross-over randomised multi-centre clinical trial to evaluate dosage and effects of CSHI in 40 Scandinavian AD patients, comparing 3 months o...

2 shares

ea0029oc7.6 | Adrenal Clinical | ICEECE2012

Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study

Di Dalmazi G. , Vicennati V. , Rinaldi E. , Morselli-Labate A. , Giampalma E. , Mosconi C. , Pagotto U. , Pasquali R.

Background: Subclinical Cushings syndrome (SCS) is defined as alterations in hypothalamicpituitaryadrenal axis without classic signs or symptoms of glucocorticoid excess. It is still controversial whether SCS leads to metabolic and cardiovascular diseases, and if the degree of subclinical hypercortisolism may predict these clinical outcomes.Aim: To evaluate the prevalence of hypertension, type-2 diabetes (T2D), coronary heart disease (C...

0 shares

Endocrine Abstracts

15th International & 14th European Congress of Endocrinology

Oral Communications

Progression-free survival without treatment of malignant pheochromocytoma and paraganglioma at one year

Activation of the PKA pathway triggers formation of an illicit serotonergic regulatory loop in primary pigmented nodular adrenal disease (PPNAD) tissues associated with Cushing’s syndrome

Ribonucleotide reductase large subunit (RRM1) gene expression predicts efficacy of adjuvant mitotane in adrenocortical cancer

Differential diagnosis of primary aldosteronism by peripheral plasma levels of 18-oxo-cortisol: a noninvasive method with a high specificity

Continuous subcutaneous hydrocortisone infusion (CSHI) as replacement therapy in Addison’s disease (AD)

Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study

BiosciAbstracts